Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02686749
Other study ID # Bio-858981
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date June 2016
Est. completion date October 1, 2018

Study information

Verified date October 2018
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multi-center, randomized, unblinded, clinical trial. The objective is to determine if catheter-based atrial fibrillation (AF) ablation is superior to medical treatment in patients with impaired left ventricular (LV) function who have been diagnosed with symptomatic AF within the past 12 months.


Description:

The purpose of the trial is to compare two different approved treatments for recently diagnosed AF: anti-arrhythmic medications and AF ablation. The study will be conducted to determine if one treatment is more effective than the other for patients with AF and heart failure. About 220 subjects with newly diagnosed AF from hospitals in the United States will take part in this study. Subjects will be randomized in a 1:1 fashion to either AF catheter ablation or anti-arrhythmic medication for treatment of AF. Both therapies are considered Standard of Care.


Recruitment information / eligibility

Status Terminated
Enrollment 220
Est. completion date October 1, 2018
Est. primary completion date July 19, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- must be 18 years of age or older

- Provide signed written Informed Consent

- symptomatic AF documented by EKG or heart rhythm monitoring within 12 months

- patients should be on optimal medical therapy for heart failure for 3 months prior to randomization. Adjustments to medications within this 3 month period are permitted.

- chronically impaired LV function defined as EF between 20%-45% within last 3 months

- all patients should be on an optimal therapy for impaired LV function

- ability to complete 6 minute walk test

- eligible for catheter ablation and anti-arrhythmic drugs

Exclusion Criteria:

- women of childbearing potential unless post- menopausal or surgically sterile

- patients hospitalized for heart failure within the 3 months prior to randomization

- reversible causes of AF such as pericarditis, thyroid disorders, acute alcohol intoxication, recent major surgical procedures or trauma

- recent reversible LV impairment that may be attributed to AF with rapid ventricular response and may improve with introduction of rate control

- valvular heart disease requiring surgical intervention

- Coronary Artery Disease (CAD) requiring surgical or percutaneous intervention

- early post-operative AF (within 3 months of surgery)

- previous MAZE or left atrial instrumentation (including ablation and left atrial appendage exclusion)

- history of Atrioventricular Node (AVN) ablation

- hypertrophic cardiomyopathy

- prolonged QT interval

- liver failure

- renal failure requiring dialysis

- social factors that would preclude follow up or make compliance difficult- history of drug, alcohol or substance abuse

- contraindications to the use of AADs and/or anticoagulation therapy

- Currently enrolled in, or discontinued within the last 30 days from a clinical trial involving an investigational product or non-approved use of a drug or device or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

- severe pulmonary disease

- documented intra-atrial thrombus, tumor, or structural abnormality which precludes catheter introduction

- unwilling to comply with protocol requirements or deemed by the investigator to be unfit for the study.

Study Design


Intervention

Device:
Catheter Ablation
During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which "disconnects" the pathway of the AF.
Drug:
FDA approved anti arrhythmic drug
Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines

Locations

Country Name City State
United States Cleveland Clinic Akron General Akron Ohio
United States Cleveland Clinic Cleveland Ohio
United States The Ohio State University Wexner Medical Center Columbus Ohio
United States Hartford Hospital Hartford Connecticut
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States University of Utah Salt Lake City Utah

Sponsors (3)

Lead Sponsor Collaborator
Oussama Wazni Biosense Webster, Inc., The Cleveland Clinic

Country where clinical trial is conducted

United States, 

References & Publications (5)

Chen MS, Marrouche NF, Khaykin Y, Gillinov AM, Wazni O, Martin DO, Rossillo A, Verma A, Cummings J, Erciyes D, Saad E, Bhargava M, Bash D, Schweikert R, Burkhardt D, Williams-Andrews M, Perez-Lugones A, Abdul-Karim A, Saliba W, Natale A. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol. 2004 Mar 17;43(6):1004-9. — View Citation

Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004 Mar 30;109(12):1509-13. Epub 2004 Mar 8. — View Citation

Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982 Apr 29;306(17):1018-22. — View Citation

Van den Berg MP, Tuinenburg AE, Crijns HJ, Van Gelder IC, Gosselink AT, Lie KI. Heart failure and atrial fibrillation: current concepts and controversies. Heart. 1997 Apr;77(4):309-13. Review. — View Citation

Wyse DG. Some recent randomized clinical trials in the management of atrial fibrillation. J Interv Card Electrophysiol. 2003 Oct;9(2):223-8. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary First hospitalization for heart failure, recurrence of AF or Direct Current cardioversion Time measured in days to first hospitalization for heart failure, recurrence of AF or Direct Current cardioversion after the treatment period (first 3 months post enrollment or post procedure during which repeat ablation can be performed and titration of AADs can be performed). 12 months
Secondary Total number of cardiovascular hospitalization total number of cardiovascular hospitalization measured by hospitalization admissions 15 months
Secondary Time to recurrence if AF lasting longer than 30 seconds time measured in days to recurrence of AF lasting longer than 30 seconds 15 months
Secondary Distance walked in a 6-mile walk test change in distance walked in 6 mile walk test 3 months through 15 months
Secondary Change in the Rand 36-Item Health Survey change in the Rand 36-Item Health Survey reflective of change in patient's quality of life 3 months through 15 months
Secondary Change in Ejection Fraction (EF) Change in Ejection Fraction heart failure measurement (percentage) baseline through15 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A